Private Advisor Group, LLC Tcr2 Therapeutics Inc. Transaction History

Private Advisor Group, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$2.11 - $2.94 $70,961 - $98,875	-33,631 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.4 - $4.71 $54,259 - $106,483	22,608 Added 205.1%	33,631 $93,000
Q4 2021 Feb 10, 2022	BUY	$4.58 - $8.34 $50,485 - $91,931	11,023 New	11,023 $52,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Private Advisor Group, LLC with notifications on news.